ACA
ABBV icon

Aptus Capital Advisors’s AbbVie ABBV Stock Holding History

Aptus Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-28,800
Closed -$2.55M – 407
2019
Q4 		$2.55M Buy
28,800
+800
+3% +$66.4K 0.18% 114
2019
Q3 		$2.12M Buy
+28,000
New +$1.92M 0.12% 117

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Aptus Capital Advisors's ABBV Position: Q2 2026 in Review

Aptus Capital Advisors increased its AbbVie (ABBV) stake by 5.4% in Q2 2026, buying an estimated $1.57M and bringing the position to 142,030 shares worth $35.7M. The position accounts for 0.24% of the portfolio, ranked #83.

Aptus Capital Advisors first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Aptus Capital Advisors held 142,030 shares of AbbVie worth $35.7M as of Q2 2026.
  • Aptus Capital Advisors bought 7,311 AbbVie shares in Q2 2026, an estimated $1.57M.
  • AbbVie made up 0.24% of Aptus Capital Advisors's portfolio in Q2 2026, its #83 holding.
  • Aptus Capital Advisors first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.